Immunoinformatic approach to design T cell epitope-based chimeric vaccine targeting multiple serotypes of dengue virus DOI
Nilanshu Manocha, Prakash Jha, Prashant Kumar

и другие.

Journal of Biomolecular Structure and Dynamics, Год журнала: 2024, Номер unknown, С. 1 - 19

Опубликована: Ноя. 28, 2024

The global dengue outbreak is a significant public health concern, with the World Health Organization recording over 3 million cases and 0.04% case fatality rate until July 2023. infection anticipated to rise in vulnerable regions worldwide. While live-attenuated vaccines are current standard, their effectiveness certain populations debated. Furthermore, presence of four closely related virus serotypes can lead antibody-dependent enhancement, compromising vaccine efficacy. In response, we propose development therapeutic subunit-vaccine based on epitopes from all induce robust cross-protective cellular immunity. Our approach involves designing multi-epitope chimeric immunogen using envelope protein virus. MHC-I MHC-II binding T-cell were selected antigen processing criteria. most potent immunodominant for each serotype, considering immunogenicity, population coverage, prediction scores, combined AAY linker peptides create stable polypeptide. Predicted be both antigenic non-allergenic, design exhibits soluble tertiary structure half-life 4.4 h mammalian systems. addition, employed an agonist toll-like receptor-4 at N-terminal downstream immunostimulatory validated through docking molecular dynamics simulations. This construct shows promise eliciting effective immune response against serotypes.

Язык: Английский

Immunoinformatic approach to design T cell epitope-based chimeric vaccine targeting multiple serotypes of dengue virus DOI
Nilanshu Manocha, Prakash Jha, Prashant Kumar

и другие.

Journal of Biomolecular Structure and Dynamics, Год журнала: 2024, Номер unknown, С. 1 - 19

Опубликована: Ноя. 28, 2024

The global dengue outbreak is a significant public health concern, with the World Health Organization recording over 3 million cases and 0.04% case fatality rate until July 2023. infection anticipated to rise in vulnerable regions worldwide. While live-attenuated vaccines are current standard, their effectiveness certain populations debated. Furthermore, presence of four closely related virus serotypes can lead antibody-dependent enhancement, compromising vaccine efficacy. In response, we propose development therapeutic subunit-vaccine based on epitopes from all induce robust cross-protective cellular immunity. Our approach involves designing multi-epitope chimeric immunogen using envelope protein virus. MHC-I MHC-II binding T-cell were selected antigen processing criteria. most potent immunodominant for each serotype, considering immunogenicity, population coverage, prediction scores, combined AAY linker peptides create stable polypeptide. Predicted be both antigenic non-allergenic, design exhibits soluble tertiary structure half-life 4.4 h mammalian systems. addition, employed an agonist toll-like receptor-4 at N-terminal downstream immunostimulatory validated through docking molecular dynamics simulations. This construct shows promise eliciting effective immune response against serotypes.

Язык: Английский

Процитировано

0